This project will provide the necessary infrastructure for basic and translational scientific discoveries in the field of pulmonary hypertension.
What is the issue for NSW?
In Australia and around the world, there is an increase in pulmonary hypertension and in a particular, a deadly subtype known as pulmonary arterial hypertension (PAH). PAH has a poor prognosis with a median survival of 6-7 years
Current treatment for pulmonary hypertension is unsatisfactory and only a minority of patients respond adequately to therapy.
What does the research aim to do and how?
The Sydney Pulmonary Hypertension Biobank is a research initiative supported by the NSW Statewide Biobank to collect and store biospecimens from patients attending expert pulmonary hypertension centres in NSW. Biospecimens will be analysed using modern molecular technologies in order to gain insights into risks factor for disease development, and predictors of disease progression and treatment response.
The collection will be linked to pre-existing large databases which contain detailed information about each participant and their long-term health outcomes. It will enable new scientific discoveries in diagnosis, prognostication and treatment of pulmonary hypertension. The hope is to develop a personalised approach to therapy based on the patient’s molecular disease profile.